Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 18

1509P - Cytokines and ductal pancreatic adenocarcinoma: Exploring their relationship with prognosis and molecular subtypes

Date

14 Sep 2024

Session

Poster session 18

Topics

Laboratory Diagnostics;  Pathology/Molecular Biology

Tumour Site

Pancreatic Adenocarcinoma

Presenters

Laura Gutierrez Sainz

Citation

Annals of Oncology (2024) 35 (suppl_2): S923-S936. 10.1016/annonc/annonc1605

Authors

L. Gutierrez Sainz1, V. Heredia2, A.M. Rodríguez García3, M.G. Crespo Sánchez4, M.G. Serrano Olmedo4, M. Molero Luis4, M. Mendiola2, J. Feliu1

Author affiliations

  • 1 Medical Oncology Department, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 2 Translational Oncology Research Laboratory, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 3 Pathology Department, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 4 Clinical Analysis Department, Hospital Universitario La Paz, 28046 - Madrid/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1509P

Background

The lack of effective predictive biomarkers remains a major challenge in the management of patients (pt) with pancreatic ductal adenocarcinoma (PDAC). Tumor microenvironment and cytokines play an important role in the prognosis of pt with PDAC. Furthermore, the simultaneous analysis of molecular subtypes of PDAC may also allow the establishment of a correlation between certain cytokines and the molecular subtype.

Methods

This is a retrospective observational study. We included all pt with PDAC from whom a plasma sample had been collected before starting the first chemotherapy treatment at La Paz University Hospital between 2016 and 2022. We measured the plasma levels of the following cytokines by a bead-based fluorescence multiplex assay: TGF-β1-3, IL-1α, IL-1β, IL-6, IL-8, IL-9, IL-10, IP-10, IL-15, IL-17A and TNF-α. The expression of GATA6 and CK17 were tested by immunohistochemistry.

Results

A total of 73 pt were included. The increase in levels of IL-1α, IL-1β, IL-6, IL-8, IL-9, and IL-15 was associated with a higher risk of progression during first-line (1L). In addition, the increase in levels of these cytokines together with TGF-β1 and TNF-α was associated with a higher risk of mortality. Higher percentiles (p) of IL-1β, IL-6 were associated with shorter PFS during 1L and higher p of IL-6, IL-8, and TNF-α were correlated with shorter OS. Multivariate analysis showed that IL-8 levels were independently associated with increased risk of progression during 1L and with mortality (Table). Elevated levels of TGF-β2 were associated with basal-like and null subtypes (p=0.040) and increased levels of IL-17A were correlated with classical and mixed subtypes (p=0.021). In the multivariate analysis, TGF-β2 levels were independently associated with basal-like and null subtypes. Table: 1509P

Variables p HR 95%CI
Multivariate analysis for PFS during 1L
IL-8 (reference group

Conclusions

The results of our study suggest that cytokines play a relevant role in the prognosis of patients with PDAC. Furthermore, their expression varies according to the molecular subtype.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.